DeutschesFachbuch.de : Angiogenesis An Integrative Approach from Science to Medicine

INHALTSVERZEICHNIS | öffnen

Contents
Preface
V
ContributorsXV
Chapter 1 History of Angiogenesis 1
Judah Folkman
Section I. Physiological & Pathological Angiogenesis: Biology of the Ang...
Chapter 2 Angiogenesis and Vascular Remodeling in Inflammation and Cancer:
Biology and Architecture of the Vasculature 17
Donald M. McDonald
Chapter 3 Endothelial Cell Activation 35
M. Luisa Iruela-Arispe
Chapter 4 Pericytes, the Mural Cells of the Microvascular System 45
Gabriele Bergers
Chapter 5 Matrix Metalloproteinases and Their Endogenous Inhibitors 55
Liliana Guedez and William G. Stetler-Stevenson
Chapter 6 Integrins in Angiogenesis 63
Alireza S. Alavi and David A. Cheresh
Section II. Angiogenesis and Regulatory Proteins
Chapter 7 Fibroblast Growth Factor-2 in Angiogenesis 77
Marco Presta, Stefania Mitola, Patrizia Dell'Era, Daria Leali, Stefania Nico...
Chapter 8 Vascular Permeability/Vascular Endothelial Growth Factor 89
Masabumi Shibuya
Chapter 9 Platelet-Derived Growth Factor 99
Andrius Kazlauskas
Chapter 10 Angiopoietins and Tie Receptors 113
Pipsa Saharinen, Lauri Eklund, and Kari Alitalo
Chapter 11 Basement Membrane Derived Inhibitors of Angiogenesis 121
Michael B. Duncan and Raghu Kalluri
Chapter 12 Angiostatin and Endostatin: Angiogenesis Inhibitors in Blood and ...
Judah Folkman
Chapter 13 Thrombospondins: Endogenous Inhibitors of Angiogenesis 147
Paul Bornstein
Section III. Molecular & Cellular Mechanisms of the Angiogenic Process
Chapter 14 Overview of Angiogenesis During Tumor Growth 161
Domenico Ribatti and Angelo Vacca
Chapter 15 Hypoxic Regulation of Angiogenesis by HIF-1169
Philip J.S. Charlesworth and Adrian L. Harris
Chapter 16 Regulation of Angiogenesis by von Hippel Lindau Protein and HIF ...
Donald P. Bottaro, Nelly Tan, and W. Marston Linehan
Chapter 17 Nitric Oxide in Tumor Angiogenesis 193
L. Morbidelli, S. Donnini, and M. Ziche
Chapter 18 VEGF Signal Tranduction in Angiogenesis 205
Harukiyo Kawamura, Xiujuan Li, Michael Welsh, and Lena Claesson-Welsh
Chapter 19 Delta-like Ligand 4/Notch Pathway in Tumor Angiogenesis 217
Gavin Thurston, Irene Noguera-Troise, Ivan B. Lobov, Christopher Daly,
John S. Rudge, Nicholas W. Gale, Stanley J. Wiegand, and George D. Yancop...
Chapter 20 Immune Cells and Inflammatory Mediators as Regulators of Tumor A...
Michele De Palma and Lisa M. Coussens
Chapter 21 Contribution of Endothelial Progenitor Cells to the Angiogenic Pr...
Marco Seandel, Andrea T Hooper, and Shahin Rafii
Chapter 22 Tumor Angiogenesis and the Cancer Stem Cell Model 249
Chris Folkins and Robert S. Kerbel
Chapter 23 Targeting the Tumor Microenvironment (Stroma) for Treatment of Me...
Isaiah J. Fidler, Cheryl Hunt Baker, Kenji Yokoi, Toshio Kuwai, Toru Nakam...
Section IV. Functional Assessments of Angiogenesis
Chapter 24 Normalization of Tumor Vasculature and Microenvironment 273
Rakesh K. Jain, Dan G. Duda, Tracy T. Batchelor, A. Gregory Sorensen, and...
Chapter 25 Targeted Drug Delivery to the Tumor Neovasculature 283
Grietje Molema
Chapter 26 Models for Angiogenesis 299
Robert Auerbach
Chapter 27 Surrogates for Clinical Development 313
Sylvia S. W. Ng and Kim N. Chi
Chapter 28 Imaging of Angiogenesis 321
Tristan Barrett and Peter L. Choyke
Chapter 29 Tumor Endothelial Markers 333
Janine Stevens and Brad St. Croix
[weiter lesen]

REGISTER | öffnen

Index
AAbegrin, 68
ABT-510, 424
Actin cytoskeleton, 210-211
Actinobacillus actinomycetemcomitans, 534
Active drug delivery, 284
AD. See Alzheimer's disease
ADAM. See A Disintegrin And Metalloproteinase
Adaptive immune cells, 225-226
Adenosine receptors, hypoxia inducible factor-1 and, 175
Adenovirus-delivered angiostatin (ADK 3), 134
ADI. See Arginine deiminase
A Disintegrin And Metalloproteinase (ADAM), 55, 58
ADK 3. See Adenovirus-delivered angiostatin
ADM. See Adrenomedullin
ADMA. See Asymmetric dimethylarginine
ADP-ribosylation, lactate and, 554-555
Adrenomedullin (ADM), hypoxia inducible factor-1 and, 173
Adriamycin, TNP-470 in vivo studies and, 401
AG-013736, 26, 28
AGENT-1 trial, 566
AGENT-2 trial, 566
Age-related macular degeneration (AMD), 333, 345, 348, 417, 426, 580
Akt/PKB, 133
Alzet, 234
Alzheimer's disease (AD), angiogenesis in central nervous system and, 496
AMD. See Age-related macular degeneration
ANCHOR trial, 349, 426
Ang 2. See Angiopoietin-2
Angiogenesis
- alternate animal models in, 306-308
- angiogenic switch, 577
- in central nervous system, 489-499
- Alzheimer's disease, 496
- - blood brain barrier formation/maintenance, 492-493
- - blood vessel maturation in, 491-492
- - cerebral amyloid angiopathy and, 496
- - cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencep...
- - cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoence...
- - cerebroretinal vasculopathy, 493
- - disease and, 493-498
- - familial amyloid angiopathies, 493
- - gliomas and, 498
- - hemangioblastomas and, 497-498
- - hereditary endotheliopathy with retinopathy, neuropathy and stroke syndrome, 493
- - hereditary vascular retinopathy, 493
- - Moya-Moya disease, 493-495
- - multiple sclerosis and, 496-497
- - Parkinson's disease and, 496
- - retinal arteriolar tortuosity, and leukoencephalopathy, 493
- - stroke and, 495
- - vascularization, 489-491
- corneal angiogenesis assay, 304-305
- coronary
- - clinical trials, 565
- - patient selection in, 567
- - randomized controlled trials, 565-567
- - therapeutic stimulation, 565
- current knowledge of, 576-577
- direct regulators of, 185-186
- - angiopoietin, 185
- - endoglin, 185-186
- - endothelin, 186
- - placental growth factor, 186
- - VEGF, 185
- genes encoding indirect regulators, 186-187
- - erythropoietin, 186-187
- - matrix metalloproteinases, 187
- - plasminogen activators, 187
- historical breakthroughs in, 575-576
- history of, 1-10
- imaging of, 321-330
- - in clinical trials, 329
- - computed tomography, 324-327
- - magnetic resonance imaging, 322-324
- - positron emission tomography, 328-329
- - single photon emission computed tomography, 328-329
- immunotherapy of, 452
- in inflammation, 18, 21
- integrins in, 63-65
- Matrigel plug assay, 305-306
- nitric oxide role in, 194
- normalization of, 8-9
- in oral cavity, 533-537
- oral mucosa wound healing and, 536
- as organizing principle, 8 pericytes in, 47-48
- regulation of
- - circulating levels of, 314-315
- - by microenvironment, 261-263
- regulatory proteins, in platelets, 9
- research, 578-579
- - flow charts, 578
- - genotype variations, 579
- - maps of, 578
- - vascular stem cells, 578-579
- - wiring diagram, 578
- research, bioassays for, 3-6
- retinal, 221-222
- sponge implant assays, 306
- tumor, 577
- - cancer stem cell and, 250-252
- - chemokines in, 229-230
- - cytokines in, 229-230
- - delta-like 4 and, 220-221
- - endothelial precursor cells and, 165-166
- - extracellular matrix in, 228-229
- - fibroblast growth factor-2 in, 82-83
- - growth factors in, 229-230
- - hematopoietic cell participation and, 165-166
- - hypoxic regulation of, 163-164
- - immune cells and, 226-227, 231-233
- - inflammatory cell role in, 164-165
- - mosaic vessels, 165
- - nitric oxide role in, 195
- - platelet-derived growth factor to, 106
- - prognostic significance of, 166
- - proteases in, 228-229
- - stem cells in, 245
- - vascular endothelial growth factor-A in, 347
- - vascular endothelial growth factor and, 416
- - vasculogenic mimicry, 165
- tumor progression and, 162
- and tumors of central nervous system, 497-498
- in vitro, 5 in
- vitro assays, 300-302
- - cell migration assay, 300-301
- - coculture protocols, 302
- - organ culture assays, 302
- - proliferation assay, 300
- - in vitro tube formation, 301-302
- in vivo assays, 302-304
- chorioallantoic membrane assay, 302-303
- mesenteric window assay, 303-304
- wound revascularization, 543-545, 550-551
Angiogenesis-dependent disease, 9-10
Angiogenesis inhibitors, 2
- antiangiogenic agents, classification of, 423-424
- in clinic, 7-8
- discovery of, 6-7
Angiogenic molecules, discovery of, 6
Angiogenic phenotype, 9
Angiogenic protein, in extracellular matrix, 6
Angiogenic regulatory network, 579, 581
Angiogenic signaling, inhibition of, 355-356
- chemistry of, 356
- BAY 43-9006 (Sorafenib), 356
- indolinones, 356
- PTK 787 (Vatalanib), 356
- ZD 6474 (Vandetanib), 356
Angiogenic switch, 161-162, 577
Angiomotin
- for angiostatin, 132
- tumor endothelial cells and, 455
Angiopoietin-2 (Ang 2), 48
Angiopoietin-receptor complex, tie receptor tyrosine kinase family and, 115
Angiopoietins, 113-114
- angiogenesis and, 185
- expression, 114
- gene-modified mice, 115-117
- ocular neovascularization and, 522-523
- signal transduction, 117
- structure of, 113-114
Angiopoietin-tie system, 117
Angiostatin, 57
- anti-inflammatory activity of, 133
- circulation and, 129-130
- clinical studies of, 135
- crystallography, 135
- delivery of, 135
- discovery of, 130
- endothelial cell surface receptors for, 131-133
- - alphav beta 3 integrin, 132
- - angiomotin, 132
- - ATP synthase, 131-132
- - CD 26, 132
- - hepatocyte growth factor receptor, 132
- - NG 2 proteoglycan, 132
- - nucleolin, 132-133
- forms of, 130-131
- gene therapy and, 134
- - experimental anti-tumor therapy, 134
- - ocular neovascularization angiostatin gene therapy, 134-135
- human neuroblastoma and, 135
- mechanism of action of, 133
- ocular neovascularization and, 524-525
- physiological angiogenesis and, 135
- protein, anti-tumor activity of, 135
- recombinant, 135
- in vivo induction of, 133-134
Animal models
- angiogenesis and alternate, 306-307
- EPCs, tumors and, 242
- VEGF-Trap and preclinical, 416-417
Annexin Al, 335
Antiangiogenic agents
- classification of, 422-424
- - angiogenesis inhibitors, 423-424
- clinical translational developmental issues of, 427-428
- in combination regimens, 432-442
- - kinase inhibitors, 435-439
[weiter lesen]